Jazz Pharmaceuticals, Inc.
United States
510 articles about Jazz Pharmaceuticals, Inc.
-
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
4/17/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.
-
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
4/10/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two oral presentations, will be featured at the 76th Annual American Academy of Neurology Meeting (AAN) being held April 13-18, 2024, in Denver.
-
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
4/2/2024
Jazz Pharmaceuticals plc announced that the company has completed the rolling submission of a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer.
-
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
3/12/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
-
Alkermes spun off its oncology business in late 2023 to become a pure-play neuroscience company, while Jazz Pharmaceuticals continues to invest in and focus on both of its businesses.
-
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
2/28/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2023 and provided guidance for 2024.
-
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
2/27/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors.
-
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
2/21/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024.
-
Jazz Pharmaceuticals to Participate in Upcoming March 2024 Investor Conferences
2/20/2024
Jazz Pharmaceuticals plc announced that Company management will participate in the following investor conferences.
-
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
2/14/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets.
-
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
2/7/2024
Jazz Pharmaceuticals plc and Redx Pharma plc announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS inhibitor program.
-
Jazz Pharmaceuticals is acquiring Redx Pharma’s KRAS inhibitor program including preclinical-stage drug candidates, with the companies working to advance assets through IND-enabling studies.
-
In a Phase II study, Jazz Pharmaceuticals’ investigational fatty acid amide hydrolase inhibitor JZP150 did not significantly improve post-traumatic stress disorder symptoms compared to placebo.
-
Recent FDA approvals of novel drugs based on less-than-stellar clinical evidence point to a trend toward regulatory flexibility—particularly in indications with very high unmet need.
-
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
12/21/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD).
-
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/20/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
-
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
12/8/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
-
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
12/1/2023
Jazz Pharmaceuticals plc today announced that nine company-sponsored presentations, including five late-breaking abstracts, will be shared at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida.
-
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
11/30/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9.
-
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
11/14/2023
Autifony Therapeutics Limited announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.